During the clinical stages of drug development, 20-30% of drugs fail due to kidney toxicity. Most current detection models cannot accurately mimic the human kidney, and too many toxic compounds enter the late stage of drug development.
ciPTEC: the solution to reduce the risk of drug failure during the clinical phase of drug development
Furthermore, the current models of predictive kidney research available are either accurate and not scalable, or scalable but inaccurate, but not both. In order to bring more successful drugs to market, Cell4pharma has developed an accurate and stable kidney cell line: ciPTEC, to enable researchers to accurately identify and remove nephrotoxic compounds in the preclinical stage of development.